Evaluation of in vitro antiviral activity of SARS-CoV-2 M pro inhibitor pomotrelvir and cross-resistance to nirmatrelvir resistance substitutions

• DOI: 10.1128/aac.00840-23
• Publication Date: 2023-10-06T13:03:41Z
• Authors: Xiao Tong; Walter Keung; Lee D. Arnold; Laura J. Stevens; Andrea J. Pruijssers; Seunghyi Kook; Uri Lopatin; Mark Denison; Ann D. Kwong
• Keywords: 0301 basic medicine; 03 medical and health sciences; SARS-CoV-2; Coronavirus 229E, Human; Humans; COVID-19; Protease Inhibitors; Pandemics; Antiviral Agents

ABSTRACT

The unprecedented scale of the COVID-19 pandemic and the rapid evolution of SARS-CoV-2 variants underscore the need for broadly active inhibitors with a high barrier to resistance. The coronavirus main protease (M pro ) is an essential cysteine protease required for viral polyprotein processing and is highly conserved across human coronaviruses. Pomotrelvir is a novel M pro inhibitor that has recently completed a phase 2 clinical trial. In this report, we demonstrated that pomotrelvir is a potent competitive inhibitor of SARS-CoV-2 M pro with high selectivity against human proteases. In the enzyme assay, pomotrelvir is also active against M pro proteins derived from human coronaviruses CoV-229E, CoV-OC43, CoV-HKU1, CoV-NL63, MERS, and SARS-CoV. In cell-based SARS-CoV-2 replicon and SARS-CoV-2 infection assays, pomotrelvir has shown potent inhibitory activity and is broadly active against SARS-CoV-2 clinical isolates including Omicron variants. Many resistance substitutions of the M pro inhibitor nirmatrelvir confer cross-resistance to pomotrelvir, consistent with the finding from our enzymatic analysis that pomotrelvir and nirmatrelvir compete for the same binding site. In a SARS-CoV-2 infection assay, pomotrelvir is additive when combined with remdesivir or molnupiravir, two nucleoside analogs targeting viral RNA synthesis. In conclusion, our results from the in vitro characterization of pomotrelvir antiviral activity support its further clinical development as an alternative COVID-19 therapeutic option.